Cargando…

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

Detalles Bibliográficos
Autores principales:	Liu, Yang, Liu, Jianying, Xia, Hongjie, Zhang, Xianwen, Zou, Jing, Fontes-Garfias, Camila R., Weaver, Scott C., Swanson, Kena A., Cai, Hui, Sarkar, Ritu, Chen, Wei, Cutler, Mark, Cooper, David, Muik, Alexander, Sahin, Ugur, Jansen, Kathrin U., Xie, Xuping, Dormitzer, Philip R., Shi, Pei-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133696/ https://www.ncbi.nlm.nih.gov/pubmed/33979486 http://dx.doi.org/10.1056/NEJMc2106083

Ejemplares similares

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Shi, Pei-Yong, et al.
Publicado: (2021)

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
por: Liu, Jianying, et al.
Publicado: (2022)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Zou, Jing, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2021)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
por: Ciabattini, Annalisa, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
por: Walter, Emmanuel B., et al.
Publicado: (2021)

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Shi, Pei-Yong, et al.
Publicado: (2020)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
por: Muñoz, Flor M., et al.
Publicado: (2023)

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
por: Plante, Jessica A., et al.
Publicado: (2020)

Author Correction: Spike mutation D614G alters SARS-CoV-2 fitness
por: Plante, Jessica A., et al.
Publicado: (2021)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
por: San Segundo, David, et al.
Publicado: (2021)

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
por: Rosenberg-Friedman, Michal, et al.
Publicado: (2021)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

The N501Y spike substitution enhances SARS-CoV-2 transmission
por: Liu, Yang, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
por: Hui, Ai-Min, et al.
Publicado: (2022)

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection
por: Arieta, Christina M., et al.
Publicado: (2023)

Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 Vaccine
por: Francavilla, Beatrice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eibkutlhff4kiu4057iosk4sm7